Rituximab in refractory Vogt–Koyanagi–Harada disease
Open Access
- 9 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Ophthalmic Inflammation and Infection
- Vol. 1 (4), 177-180
- https://doi.org/10.1007/s12348-011-0027-9
Abstract
Vogt–Koyanagi–Harada (VKH) prognosis depends on early recognition and treatment; chronic disease may be developed when either delayed or inadequate treatment is performed, whereas other cases despite correct treatment are refractory to different drugs and also become chronic. We report a case of refractory VKH controlled with rituximab treatment.Keywords
This publication has 14 references indexed in Scilit:
- Rituximab for UveitisOphthalmology, 2011
- Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt–Koyanagi–Harada diseaseAlbrecht von Graefes Archiv für Ophthalmologie, 2010
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated OphthalmopathyOphthalmology, 2010
- Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada diseaseBritish Journal of Ophthalmology, 2009
- Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosisBritish Journal of Ophthalmology, 2007
- Tratamiento con Adalimumab -nuevo antiTNF- del síndrome de Vogt-Koyanagi-HaradaArchivos de la Sociedad Española de Oftalmología, 2007
- Immunomodulatory Therapy for Vogt-Koyanagi-Harada Patients as First-Line TherapyOcular Immunology and Inflammation, 2006
- Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndromeAmerican Journal of Ophthalmology, 2004
- Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada DiseaseAmerican Journal of Ophthalmology, 2001